| Title: | Do the benefits of sodium-glucose cotransporter 2 inhibitors exceed the risks in patients with type 1 diabetes? |
| Authors: | Kamoshima, Hikaru Browse this author |
| Nomoto, Hiroshi Browse this author →KAKEN DB |
| Yamashita, Kumiko Browse this author |
| Takahashi, Yuka Browse this author |
| Tsuchida, Kazuhisa Browse this author |
| Kuwabara, Saki Browse this author |
| Miya, Aika Browse this author |
| Cho, Kyu Yong Browse this author |
| Kameda, Hiraku Browse this author →KAKEN DB |
| Nakamura, Akinobu Browse this author →KAKEN DB |
| Atsumi, Tatsuya Browse this author →KAKEN DB |
| Taneda, Shinji Browse this author |
| Kurihara, Yoshio Browse this author |
| Aoki, Shin Browse this author |
| Ono, Yuri Browse this author |
| Miyoshi, Hideaki Browse this author →KAKEN DB |
| Keywords: | Key words |
| Sodium-glucose cotransporter 2 inhibitor |
| Type 1 diabetes |
| Diabetic ketoacidosis |
| Issue Date: | 28-Jan-2022 |
| Publisher: | 社団法人 日本内分泌学会 |
| Journal Title: | Endocrine journal |
| Volume: | 69 |
| Issue: | 5 |
| Start Page: | 495 |
| End Page: | 509 |
| Publisher DOI: | 10.1507/endocrj.EJ21-0573 |
| Abstract: | Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are well-established means of improving glycemia and preventing cardio-renal events in patients with type 2 diabetes. However, their efficacy and safety have yet to be fully characterized in patients with type 1 diabetes (T1D). We studied patients with T1D who regularly attended one of five diabetes centers and treated with an SGLT2i (ipragliflozin or dapagliflozin) for 52 weeks, and the changes in HbA1c, body mass, insulin dose, and laboratory data were retrospectively evaluated and adverse events (AEs) recorded during December 2018 to April 2021. A total of 216 patients with T1D were enrolled during the period. Of these, 42 were excluded owing to short treatment periods and 15 discontinued their SGLT2i. The mean changes in glycated hemoglobin (HbA1c), body mass, and insulin dose were -0.4%, -2.1 kg, and -9.0%, respectively. The change in HbA1c was closely associated with the baseline HbA1c (p < 0.001), but not with the baseline body mass or renal function. The basal and bolus insulin doses decreased by 18.2% and 12.6%, respectively, in participants with a baseline HbA1c <8%. The most frequent AE was genital infection (2.8%), followed by diabetic ketoacidosis (DKA; 1.4%). None of the participants experienced severe hypoglycemic events. In conclusion, the administration of an SGLT2i in addition to intensive insulin treatment in patients with T1D improves glycemic control and body mass, without increasing the incidence of hypoglycemia or DKA. |
| Type: | article |
| URI: | http://hdl.handle.net/2115/83940 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
